Public Alert No:005/2023 – Alert on Substandard and Falsified Medical Products seized in Cote d’Ivoire
March 8, 2023,
The National Agency for Food and Drugs Administration and Control (NAFDAC) is notifying the public of the information received from Autorité Ivoirienne de Régulation Pharmaceutique (AIRP) on some Substandard and Falsified Medical Products with alleged NAFDAC number seized in Côte d’Ivoire.
According to the Ivorian authority, the AIRP inspectors identified certain products bearing NAFDAC registration number on their secondary package while taking inventories of seized SF medical products.
It is within the framework of sub-regional fight against SF medical products and the collaborative relationship that exists between Nigeria and Côte d’Ivoire, that the AIRP disclosed this information to NAFDAC.
Although the underlisted products were registered by NAFDAC, their registration status has long expired and are yet to be renewed. Hence, the quality and safety of the products can no longer be guaranteed.
The details of the drugs seized are as follows;
|Name of Product||GOCEE Chloroquine Injection 322mg/5ml B/10 ampoules||DEX-UP
Dexamethasone tablet 0.5mg B/10
|CIMETIDINE Injection 200mg B.P IM/IV
|SUPASTO Forte 550 Paracetamol & Diclofenac tablets B/10
|Product Manufacturer||Shandong Xier Kangtai Pharm Co., Ltd.||Suitelife Pharmaceutical Ltd.
|Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd
|Mancare Pharm Pvt Ltd
|Language used in the packaging||English||English||English||English|
|Countries in which products have been identified||Ivory Coast||Ivory Coast||Ivory Coast||Ivory Coast|
Importers, distributors, retailers and consumers are therefore advised to exercise caution and vigilance within the supply chain to avoid the importation, distribution, sale and use of the above mentioned products. All medical products must be obtained from authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked.
Members of the public in possession of the above listed products are advised to discontinue sale or use and submit stock to the nearest NAFDAC office.
If you have batches of the products, please DO NOT use them. If you, or someone you know, have used these products, or suffered any adverse reaction/event after use, you are advised to seek immediate medical advice from a qualified healthcare professional.
Healthcare professionals and consumers are advised to report any suspicion of Adverse drug reaction, substandard and falsified medicine to the nearest NAFDAC office or contact NAFDAC on 0800-162-3322 or via email: email@example.com
Healthcare professionals are also encouraged to report adverse events or side effects related to the use of these products via the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng or via the Med- safety application for download on android and IOS stores or via e-mail on firstname.lastname@example.org